AzurRx (AZRX) Corporate Media Kit

27 Trial Design • Bridging dose safety study • N = 32 Results • Safety confirmed in CF patients at 2.2g per day: no serious adverse events observed • Modified ITT showed MS1819 CFA results of 56% vs. PERT CFA of 86% • Approximately 50% of patients showed CFAs sufficient to reach non-inferiority with PERT Additional findings • No need for protease • Coefficient of Nitrogen Absorption (CNA) of 93% MS1819 vs 97% PERT Phase 2 Cystic Fibrosis OPTION Study